Dublin, April 29, 2026 (GLOBE NEWSWIRE) — The “Biologics CDMO Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The biologics CDMO market is experiencing tremendous growth, with market size projected to expand from $24.15 billion in 2025 to $27.56 billion by 2026, at a CAGR of 14.1%. This increase can be attributed to advancements in cell culture technology, rising prevalence of chronic diseases, growth in biosimilar pipelines, and significant governmental support for biopharma manufacturing. The market is expected to further accelerate, reaching $48.07 billion in 2030, driven by the rise in gene and cell therapy development, automation and robotics adoption in CDMO processes, and the expansion of global biologics manufacturing capacity.
The projected growth brings forward trends such as an increased focus on mammalian cell-based production and a rise in outsourcing gene therapy manufacturing. As technology advances, there is a noticeable shift towards biosimilars and precision medicine, which is boosting demand for cost-effective biologics production. Increasing demand for cell and gene therapies is a significant growth driver, with innovative therapies potentially treating conditions traditionally deemed difficult to manage.
According to IQVIA Holdings Inc., global spending on cell and gene therapies climbed to $5.9 billion in 2023, rising 38% from 2022. Biologics CDMOs play a crucial role in this landscape by offering specialized services to handle living cells and genetic materials safely. They enable pharmaceutical companies to meet regulatory requirements and ease the transition from research to clinical applications.
Technological advancements are at the forefront of this industry, as evidenced by companies like Lonza Group. In November 2023, they introduced GS Effex cell lines aimed at improving therapeutic antibody potency for immunotherapy applications. Such innovations support therapeutic development from research through to commercial manufacturing.
Strategic acquisitions are propelling growth in the sector; Novo Holdings A/S acquired Catalent, Inc. in December 2024 to enhance its CDMO capabilities and diversify its drug development solutions. This move represents a significant step towards expanding in the biologics CDMO space, aligning with Catalent’s expertise in advanced delivery technologies and manufacturing services.
North America dominated the biologics CDMO market in 2025, but Asia-Pacific is predicted to be the fastest-growing region through 2030, with countries like India, China, and South Korea playing significant roles. Tariffs present challenges by increasing costs for imports, but they also encourage local sourcing and investment in domestic manufacturing capabilities, driving the adoption of cost-efficient biologics production technologies.
Key players in the market include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, and Thermo Fisher Scientific Inc, among others. These companies are focusing on expanding services, improving mammalian cell production, and leveraging advanced bioprocessing techniques to stay competitive.
The biologics CDMO market encompasses a wide array of services including process and analytical development, cell line development, supply chain management, and fill-finish services. This comprehensive approach ensures robust growth opportunities, addressing the evolving needs of the biopharmaceutical sector.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $27.56 Billion |
| Forecasted Market Value (USD) by 2030 | $48.07 Billion |
| Compound Annual Growth Rate | 14.9% |
| Regions Covered | Global |
Report Scope:
Markets Covered:
- Cell Type: Mammalian; Non-Mammalian
- Product Type: Biologics; Biosimilars
- Service Type: Drug Substance Manufacturing; Drug Product Manufacturing; Process Development; Analytical & Quality Testing Services
- Subsegments include Mammalian Cells like CHO and HEK, and Non-Mammalian Cells like Yeast and Bacterial.
Major Trends
- Expansion of Biologics Cdmo Services
- Growth in Mammalian Cell-Based Production
- Increase in Outsourcing of Gene Therapy Manufacturing
- Adoption of Advanced Bioprocessing Techniques
- Rising Demand for Biosimilars
Companies Featured
- Lonza Group Ltd
- Samsung Biologics Co Ltd
- WuXi Biologics Cayman Inc
- Catalent Inc
- Thermo Fisher Scientific Inc
- Boehringer Ingelheim International GmbH
- Emergent BioSolutions Inc
- Grifols SA
- AbbVie Inc
- Novartis AG
- Sandoz International GmbH
- Fujifilm Holdings Corporation
- AGC Inc
- JSR Corporation
- Shenzhen Hepalink Pharmaceutical Co Ltd
- Kemwell Biopharma Pvt Ltd
- Bora Pharmaceuticals Co Ltd
- Binex Co Ltd
- 3P Biopharmaceuticals SLU
- Cytovance Biologics
For more information about this report visit https://www.researchandmarkets.com/r/s0oczw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
